Dr. Sullivan's focus is on the role of epithelial-derived chemokines in the pathogenesis of idiopathic pulmonary fibrosis. He works primarily with cell and animal-based models of disease in an effort to develop novel therapeutics for fibrosing lung diseases.
Dr. Sullivan is interested in augmenting the progression of interstitial lung disease. He nurtures this clinical interest by seeing patients at the Simmons Center for Interstitial Lung disease where clinical trials of therapeutics are underway.
Dr. Sullivan's educational interest is in increasing the application of scientific principles to the management of patients.
- BS, Chemical and Biological Engineering, University of Alabama, 2009
- MD, University of Alabama School of Medicine, 2014
- Residency, Internal Medicine, University of Texas Southwestern Medical Center, 2017
- Fellowship, Pulmonary and Critical Care Medicine, University of Pittsburgh School of Medicine, 2020
Education & Training
Jiang, M., Roth, M. G., Chun-On, P., Sullivan, D. I., Alder, J. K. Phenotypic Diversity Caused by Differential Expression of SFTPC-Cre-Transgenic Alleles. American Journal of Respiratory Cell and Molecular Biology. 2020; 62(6): 692-698.
Sullivan, D. I., Kass, D. J. Signals and signposts: Biomarkers in IPF and PAH at the crossroads of clinical relevance. Respirology. 2019; 24(11): 1044-1045.
Sullivan, D., Ahn, C., Gao, A., Lacelle, C., Torres, F., Bollineni, S., Banga, A., Mullins, J., Mohanka, M., Ring, S., Wait, M., Pelts, M., Duddupudi, P., Surapaneni, D., Kaza, V. Evaluation of current strategies for surveillance and management of donor-specific antibodies: Single-center study. Clinical Transplantation. 2018; 32(7)
- Howard Hughes Medical Institute Medical Research Fellowship, 2013
